Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with triple-negative breast cancer (a specific type of breast cancer identified through lab testing of tumour tissue).
- People with early-stage breast cancer (stage I, II, or III) who are planned to receive chemotherapy before surgery, with the goal of curing the cancer.
- People who have been fully informed about the nature of the study and what taking part involves.
- People who are able to understand and are willing to sign a written consent form as required by the institution and relevant guidelines.
- People who are 18 years of age or older.
- People who are scheduled to begin chemotherapy before surgery (and have not yet started).
- People who are willing to provide blood samples before and during treatment.
- People who have tumour tissue from a biopsy available for testing.
Who may not be able to join:
- People who are currently receiving cancer treatment for a different cancer at the same time.
- People whose cancer has spread to distant parts of the body (stage IV).
- People who have had another primary cancer diagnosed within the past 5 years, unless it was a common type of non-spreading skin cancer or a non-invasive cancer.
- People who have previously had a bone marrow or organ transplant from another person.
- People who have received a blood transfusion within two weeks before the blood sample for a key test is collected.
- People who have already started any drug treatment for their breast cancer.
- People who are pregnant.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pavani Chalasani, George Washington University
Phone: 484-704-2599
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate the correlation of MRD to pCR after NAC in TNBC
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.